ABSTRACT
It has been recognized for many years that testicular dysfunction is relatively common following treatment with cytotoxic chemotherapy and radiotherapy. The number of malignancies that are potentially treatable has increased over the last few decades. This, coupled with the improving long-term survival rates of many cancers, has meant that the number of surviving patients who have received cytotoxic therapy or radiotherapy is growing rapidly, and cancer treatment is becoming an increasingly common cause of acquired testicular dysfunction.
